Comparison of efficacy and safety in two versus three cycles of neoadjuvant immunotherapy plus chemotherapy for esophageal squamous cell carcinoma
Two-cycle neoadjuvant immunotherapy combined with albumin-bound paclitaxel and platinum based chemotherapy can be an effective, safe, and optional neoadjuvant strategy for esophageal squmous cell carcinoma patients.
Authors
- Jie Jiang (ORCID: https://orcid.org/0000-0002-2739-6995)
- Xiaolei Zhu
- Guanzhi Ye (ORCID: https://orcid.org/0000-0002-7279-2567)
- Hongming Liu (ORCID: https://orcid.org/0000-0003-4420-3160)
- Gaojian Pan
- Guojun Geng
Institutions
- First Affiliated Hospital of Xiamen University (CN)
Publication Details
- Journal
- Journal of Cardiothoracic Surgery
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1186/s13019-025-03587-4
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Fujian Province